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Abstract—In this paper, we present the design and the analysis of 
an electrochemical circuit for measuring the concentrations of 
therapeutic drugs using structure-switching aptamers. Aptamers 
are single-stranded nucleic acids, whose sequence is selected to 
exhibit high affinity and specificity toward a molecular target, and 
change its conformation upon binding. This property, when 
coupled with a redox reporter and electrochemical detection, 
enables reagent-free biosensing with a sub-minute temporal 
resolution for in vivo therapeutic drug monitoring. Specifically, we 
design a chronoamperometry-based electrochemical circuit that 
measures the direct changes in the electron transfer (ET) kinetics 
of a methylene blue reporter conjugated at the distal-end of the 
aptamer. To overcome the high-frequency noise amplification 
issue when interfacing with a large-size (> 0.25 mm2) implantable 
electrode, we present a sample-and-hold (S/H) circuit technique in 
which the desired electrode potentials are held onto noiseless 
capacitors during the recording of the redox currents. This allows 
disconnecting the feedback amplifiers to avoid its noise injection 
while reducing the total power consumption. A prototype circuit 
implemented in 65-nm CMOS demonstrates a cell-capacitance-
insensitive input-referred noise (IRN) current of 15.2 pArms at a 
2.5-kHz filtering bandwidth.  Tested in human whole blood 
samples, changes in the ET kinetics from the redox-labeled 
aminoglycoside aptamers at different kanamycin concentrations 
are measured from the recorded current waveforms. By 
employing principal component analysis (PCA) to compensate for 
the sampling errors, a detection limit (SNR = 1) of 3.1 µM under 
1-sec acquisition is achieved at 0.22-mW power consumption. 
 
Index Terms— Aptamer, DNA, personalized drug dosing, 
precision medicine, pharmacokinetics, electrochemical detection, 
square-wave voltammetry, chronoamperometry, methylene blue, 
electron transfer kinetics, in vivo monitoring, CMOS, implantable, 
wearable, sample-and-hold circuit, principal component analysis, 
aminoglycoside, kanamycin. 
I. INTRODUCTION 
Current clinical standard for drug dosing relies on physical 
parameters, such as age, gender, body weight, and body surface 
area. Unfortunately, these approaches do not account for 
individual differences in pharmacokinetics (PK), which 
describes the absorption, distribution, metabolic, and excretion 
rate of drugs in the body [1–3]. As PK between individuals can 
exhibits difference as large as tenfold [4], there is great interest 
in developing the technology for monitoring and controlling 
drug concentrations in vivo for optimal therapeutic outcomes at 
minimal toxicity (Fig. 1(a)) [5–7]. Such control is particularly 
important for drugs with narrow “therapeutic windows” 
wherein underdosing results in low efficacy and over-dosing 
can cause acute injury to organs [8–10]. Today, therapeutic 
drug monitoring (TDM) requires multiple venous blood draws 
and samples are analyzed using immunoassays [11–12] or high-
performance liquid chroma-tography/mass-spectroscopy 
(HPLC/MS) [13–14]. These assays require hours of processing 
which is insufficient for optimal drug dosing. Thus, there is a 
pressing need for continuous biosensor that can measure drug 
levels in real-time.  Importantly, such a sensor would enable the 
development of closed-loop systems for automatically 
delivering optimal doses of drugs to individual patients 
regardless of their PK profile. (Fig. 1(b)). 
To this end, our group and others have previously utilized 
aptamers to achieve continuous detection of drugs in vivo [15–
21]. Aptamers are “synthetic antibodies” composed of nucleic 
acids that can specifically bind to the target analytes in complex 
samples such as the whole blood [22–24]. Importantly, they 
can be engineered into “aptamer-switches” that undergo 
structure-switching upon target binding in a reversible manner. 
By conjugating electroactive reporters to the aptamers, the 
changes in their structure (thus the analyte concentration) can 
be detected electrochemically. As sample preparation is not 
needed, aptamer switches are capable of continuous monitoring 
of biomolecules in vivo.   
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Fig. 1. (a) Real-time therapeutic drug monitoring enables precision drug dosing 
for optimal treatment outcome. (b) A generic closed-loop drug control system. 
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Nevertheless, the current generation of aptamer-based real-
time biosensors requires either a continuous drawing of the 
subject’s blood [15] or wired connection to an implanted device 
[16], and both systems are only suitable for non-ambulatory 
patients. To overcome these limitations, we have previously 
reported a miniaturized CMOS system for implantation [25]. 
However, this system consumed milliwatts of power, 
dominated by the signal-to-noise ratio (SNR) requirement in the 
sensing circuits when interfacing with large-area-electrodes for 
in vivo monitoring. Moreover, the readout utilizes square-wave 
voltammetry (SWV) with a long acquisition time (~8 sec), 
leading to an excessively high energy consumption (> 50 mJ/ 
sample). This motivates us to develop circuit techniques that 
can overcome such a noise-power trade-off 
Several electrochemical-sensing current-readout circuits 
have been developed for in vitro DNA and biomolecule analysis 
[26–31], in vivo glucose and lactate monitoring [32–34], and 
sub-second neurotransmitter detection [35–38]. In these 
implementation, transimpedance amplifier (TIA) and current 
conveyor (CC) are two popular circuits topologies for reading 
small currents. As both employ transconductance amplifiers 
(OTAs) in feedback to establish proper electrode potentials, it 
is inevitable to couple the OTA noise to the impedance of the 
electrochemical cell, resulting in noise amplification when 
measured at high bandwidth (> 1 kHz). This is especially 
problematic in our specific applications. 
In this work, we present a sample-and-hold (S/H) technique 
in chronoamperometry (CA) to overcome the noise/power 
trade-off when detecting aptamer conformation switching [39]. 
By holding the desired potentials onto the electrodes using 
capacitors, we successfully record, for the first time, the 
changes in the electron-transfer (ET) kinetics of the redox 
reporters without OTAs. Such an open-loop scheme enables 
simultaneous reduction in both the circuit noise and the power 
consumption. As a proof-of-concept, we used our circuit with 
an aminoglycoside aptamer [15] to measure kanamycin 
concentrations and achieved limit-of-detection (LoD) that is on-
par with benchtop laboratory instruments. Built upon [39], this 
paper provides more details regarding the signal transduction 
mechanism and the analysis that assists the mapping between 
the electronics noise and the measurement uncertainty in 
molecular concentration. The issue of sampling error will be 
discussed, and a compensation technique is presented. 
This paper is organized as follows. Section II describes the 
sensing mechanism and the detection schemes for the aptamer 
switches. The proposed circuit architecture, signal and noise 
analysis, as well as its implementation are introduced in Section 
III. Section IV presents the experimental results, covering both 
the electronics characterization and assay experiemtns.  
Conclusions are presented in Section V. 
II. APTAMER SWITCHES 
A. Sensing Mechanism 
As described above, our group has utilized structure-
switching aptamers to achieve real-time detection of small-
molecule drugs in vivo [15][17]. Using the aminoglycoside 
aptamer as an example (Fig. 2), the binding to the target 
molecules promotes a more thermodynamically stable stem-
loop structure (folded) instead of a linear and flexible structure 
(unfolded). By conjugating the aptamers with a methylene blue 
(MB, C16H18ClN3S) reporter at the distal end of the DNA, such 
a conformation change can be detected by measuring the 
differences in the electron-transfer kinetics of MB through its 
sensitivity to the diffusion distance versus the underlying 
electrode [40–41]. The highest ET kinetics occurs when the MB 
is closer to the electrode, resulting in a larger electrical current 
when measured in voltammetry. In this way, higher drug 
concentration will cause more aptamers being switched into the 
stem-loop configuration, and thus a larger accumulated signal. 
In our system, these aptamers are immobilized at the tip of a 
sensing probe, which can be implanted directly into a vein for 
measuring drug concentration in blood plasma. 
B. Square-wave Voltammetry 
The states of the aptamers are generally measured using 
square-wave voltammetry (SWV; Fig. 3(a)) [15–16, 40–41]. 
Unlike cyclic voltammetry (CV), SWV measures the ET 
kinetics through continuous modulation of the MB states using 
a small-amplitude square-wave superimposed on a stepping 
voltage established between a reference (RE) and a working 
electrodes (WE). This effectively separates the non-Faradaic 
currents (charging and discharging currents of the interfacial 
double-layer capacitance) from the desirable Faradaic 
components (from redox reactions), relaxing the dynamic range 
requirement and enhancing the sensitivity [40]. Fig. 3(b) 
depicts example measurements at different kanamycin 
concentrations (in buffer) using a commercial potentiostat 
 
Fig. 2. The operation of structure-switching aptamer with and without the 
presence of the drug and its use in in vivo monitoring. 
 
 
Fig. 3. (a) SWV operation. (b) SWV voltammograms at 400 Hz at different 
kanamycin concentrations. (c) Measured time-series at 400 and 60 Hz SWV 
frequencies. (d) Fitting of the binding curve with Langmuir isotherm model. 
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(Palmsens EmStat3 Blue). To mitigate sensor drifts, we employ 
kinetic differential measurement (KDM) technique [15], which 
takes advantage of the sensitivity difference measured at two 
SWV frequencies (e.g. 400 and 60 Hz) to reject common-mode 
drift while preserving the desired signal (Fig. 3(c)). The 
molecular limit-of-detection (LoD), defined at SNR = 1, is 1.5 
µM for amino-glycoside aptamer with a dissociation constant 
(KD) of 0.5 mM for kanamycin (extracted from the binding 
curve in Fig. 3(d) with a Langmuir isotherm model). These 
numbers will be used later for benchmarking electronics 
performance. One critical drawback of SWV is the long 
scanning time (~8 sec per acquisition), which translates to 
significantly higher energy consumption per readout sample. 
C. Chronoamperometry 
Though SWV has been the mainstream for electrochemical-
based aptamer sensing, chronoamperometry (CA) has recently 
been re-investigated for redox-coupled DNA detection [42–43]. 
As shown in Fig. 4, chronoamperometry operates by pulsing the 
electrode potential (VWE – VRE) between two largely-separated 
voltage levels (V1 – V2 > 200 mV) to modulate the energy states 
of the redox molecules from the fully-reduced toward oxidation 
(and vice versa). The kinetics of the electron transfer is then 
probed directly through measurements of the decaying current 
transients. Chronoamperometry offers three main advantages 
over SWV: (1) higher temporal resolution due to the absence of 
potential scanning; (2) reduced sensitivity to the drifts in the 
absolute current (rate measurements); and (3) minimal 
influence from background interference due to a limited 
voltage-scanning range (Table I). More importantly, its 
operational simplicity offers an opportunity to incorporate 
circuit technique for simultaneous power and noise reduction, 
as will be discussed in Section III-C. Nevertheless, CA is more 
sensitive to the instability of the RE potential because any drift 
in the redox potential will remain undetectable and leads to 
signal variation. Such an issue can be solved with a hybrid 
scheme using SWV (or cyclic voltammetry) to frequently 
calibrate and re-adjust V1 and V2 [37]. In our device, the 
oxidation (reduction) potential of the MB measured from our 
device is located at -0.3V (-0.4V), and hence V1 and V2 are 
selected as -0.2V (-0.3V) and -0.4V (-0.5V). 
D. Measurement Uncertainty  
It is crucial to study factors that impact the performance of 
the biosensor performance in vivo. Generally, the uncertainty in 
the assay (𝑒!""!#$ ) is summarized as [44]: 
 
             𝑒!""!#$ = 𝑒%,'(')*+,%-)"$ + 𝑒%,./0$ + 𝑒1!)23+,4%5$ ,     (1) 
 
where 𝑒%,'(')*+,%-)"$  refers to the noise from the measurement 
electronics, 𝑒%,./0$  represents the shot noise induced by both the 
molecular binding and the electron transfer in the redox reaction, 
and 𝑒1!)23+,4%5$  includes all other uncertainty such as drifts, 
sensitivity degradation, non-specific binding, and curve-fitting 
errors. We carried out both in vitro (using flowing human whole 
blood) and in vivo (using an anesthetized rodent) studies to 
monitor aptamer responses under changing drug concentration. 
Fig. 5 demonstrates an example of in vivo setup, our 
implantable device (which will be used later when testing the 
proposed sensor circuits), and the measurement results (in 
SWV). We found that 𝑒1!)23+,4%5$  occurs at a longer time scale 
(~ hours) and can be corrected with in vitro calibration, similar 
to the approach used in continuous glucose monitoring (CGM) 
system [45], and 𝑒%,./0$  is negligible due to relatively high 
target concentration in our drug-dosing application. On the 
other hand, 𝑒%,'(')*+,%-)"$  plays the dominant role in determining 
the sample-to-sample variance. This is indeed the case in our 
earlier CMOS implementation [25] where we measured an LoD 
of only 18 µM (≈ 0.036KD).   
Note that Vpeak in the acquired SWV curves is shifted by ~15 
mV in the 3hr in vivo experiments due to the drift in the pseudo-
RE. We adjusted the upper and lower bounds of the scanned 
voltages to re-center Vpeak for measurement consistency. As 
 
Fig. 4. Chronoamperometry operation. 
 
Table I. A comparison between SWV and CA. 
 
 
Fig. 5. (a) in vivo demonstration with a rodent model. (b) The photo of the 
implanted probe. (c) Measured responses of two aptamers. 
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mentioned earlier, such an adjustment is particularly important 
in CA measurements. 
E. Implantable Probe 
To fit into the vein of a rodent, we prepare an implantable 
probe (Fig. 5(b)) consisting of a bundle of a gold (Au, the WE) 
and a silver chloride (Ag/AgCl, the RE) wires, all at 75-µm 
diameter. The sensing area on the gold electrode is defined 
using heat-shrinkable polymer tubing. Here we employed a 
two-electrode electrochemical cell instead of a standard three-
electrode setup. This is possible because the electrolyte 
resistance between the RE and WE is sufficiently small such 
that the IR drop between them is negligible. The aptamers are 
immobilized onto the oxidized gold wire through thiol bonds 
(S-H). The device is implanted through the femoral vein using 
a 20-gauge catheter. The system can be scaled up by bundling 
extra gold wires functionalized with different aptamers to 
monitor more than one type of drugs. Fig. 5(c) demonstrates the 
results of a multiplexed drug detection with bolus 
administration of two drugs (kanamycin and ampicillin) 
intravenously at different time instants. The sequence of 
aptamers for detection ampicillin is adapted from [46]. 
It is critical to point out the importance of aptamer packing 
density on the electrode. On one hand, excessively high packing 
density induces undesired inter-molecular interactions among 
the aptamers and cause sensitivity degradation.  On the other 
hand, excessively low packing density produces small signals. 
In general, we  prepare the aptamers at a surface density of 1% 
which produces an optimal signal [47]. This translates to a 10-
nm average spacing among each aptamer assuming each one 
occupies a real estate of 1 nm2, or 1012/cm2.  To cope with such 
a low surface density, we have chosen a relatively large area (> 
0.25 mm2) in our implantable sensing probe to achieve a 
sufficiently large signal without the need of surface roughening 
[48] and to avoid the issue of irreversible oxygen reduction 
encountered when using a small-area electrode [49]. Inevitably, 
such a large cell capacitance will have system design 
implications and causes significant noise amplification, which 
will be discussed in Section III-A. 
III. APTAMER-SENSING CIRCUITS 
A. Signal Analysis and Design Specification 
In this section, we focus on understanding the impact of 
electronics noise to the LoD of the measured drug concentration 
in chronoamperometry. Before starting, it is important to 
mention that the extraction of the concentration information 
from the decaying current waveforms involves curve-fitting 
technique.  Such an “averaging” effect on the electronics noise 
must not be neglected otherwise the design specification will be 
overly conservative. Our approach is detailed in the next 
paragraph. 
To simplify the noise analysis, we model the ET kinetics 
using an exponential function with a time constant 𝜏%1 (Fig. 6): 
 
                                     𝑖+'5,6(𝑡) = !"7#8  𝑒& !"# .      (2) 
In (2), QT represents the total charge when all the MB electrons 
(two electrons per molecule) are fully transferred during the 
redox reaction, and α accounts for the percentage of the MB that 
participates in the electron transferring. The weighting term 
ensures that the total amount of transferred charges under 
varying 𝜏%  remains constant. Next, we perform Monte Carlo 
simulation with Gaussian white noise added to the time series 
and the curve is fitted (fit function in Matlab) to extract the 
kinetical time constant. The procedure is repeated multiple 
times at different noise magnitude, and the uncertainty (one 
standard deviation) in the time constant is calculated. Finally, 
we map the electronics noise to the molecular concentration 
assuming a known sensitivity (S = ∆τ0 / ∆[C]).  
Fig. 6 shows the calculated current for a 0.25-mm2 (= 500 µm 
´ 500 µm) electrode at 1% packing density. Here we assume a 
time-constant ratio of 2:1 at high and low target concentration 
based on our earlier experiments. According to our simulation, 
an additive noise magnitude of < 0.25nArms (sampled at 2.5 kHz 
over 10 msec) is needed to ensure that the concentration 
uncertainty is kept below 0.01KD. The readout IC requires 
approximately 10 bits of dynamic range with the maximum 
 
Fig. 6. Monte Carlo simulation for studying impact of electronics noise. 
 
Table II. Design Specification 
 
Deriving the actual current response under overpotential activation requires 
solving the mass transport kinetics using Fick’s law of diffusion and Butler-
Volmer equation [50–51], and this often requires numerical simulation based 
on the electrode geometry [41]. 
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signal determined by the fastest electron transfer kinetics (k ~ 
440 1/sec) [40]. We summarize the design specification for both 
the biosensor and the electrochemical-sensing interface circuits 
in Table II. 
The electron transfer kinetics is also impacted by the use of 
the self-assembly monolayer (SAM) for passivating the sensor 
surface. Such passivation is necessary to block the undesirable 
redox reaction from the electroactive biomolecules presented in 
the biofluids, including oxygen, uric acids, ascorbic acids, and 
etc. In our in vivo assay, we employ 6-mercapto-1-hexanol 
(MCH; C6H14OS, a hydroxyl-terminated six-carbon chain) to 
serve this purpose and to balance between electron transfer 
kinetics and the stability of the SAM [52]. The presence of the 
passivation also affects the double-layer capacitance at the 
electrode-electrolyte interface. The measured double layer 
capacitance (CDL) exhibits a unit capacitance of 36 and 215 
nF/mm2 with and without the passivation, respectively. The 
estimated CDL for our implanted electrode is also included in 
Table II. In our circuit design, we have started with CDL = 100 
nF as the worst-case scenario (assuming no passivation and 
taking into account variation in the sensor surface area). 
B. Electrochemical-sensing Interface Circuits 
Fig. 7 shows the conventional electrochemical readout circuit 
[25]. It consists of a bandgap reference (BGR) voltage 
generator, a reference buffer (A1), an R-2R digital-to-analog 
converter (DAC), a control amplifier (A2), a current conveyor 
(CC) with feedback amplifier (A3), and an analog-to-digital 
converter (ADC). The total noise current, when referred to the 
input of the current conveyor (or WE), is the power sum of the 
electrochemical-cell-dependent noise and the additive noise 
from the current conveyor: 
 
                           𝚤%,9:$))))))) = 𝚤%,;$)))) + 𝚤%,$$)))),                              (3) 
 𝚤%,;$)))) = 	%<,=>?@&&&&&&&&&&'%<,ABC@&&&&&&&&&&'	%<,BD@&&&&&&&'	%<,B@@&&&&&&&'	%<,BE@&&&&&&&|)FGHH|@  ,         (4) 
 
𝚤%,$$)))) = 𝚤%,I1J!"$))))))))) + 𝚤%,.;$)))))) + 𝚤%,.$$)))))) + *+KLMMNM@  𝚤%,OPQ$)))))))).      (5) 
 
In (4), Zcell (= Rs + 1/jωCDL) models the electrical impedance of 
the electrochemical cell, and 𝑣%,RST$)))))))), 𝑣%,POQ$)))))))), 𝑣%,O;$))))))), 𝑣%,O$$))))))), 𝑣%,OU$))))))) 
are the output noise of the bandgap reference, the DAC, and the 
input-referred voltage noise of the amplifiers A1-3, respectively; 
in (5), Nmirror is the gain of current mirror, 𝚤%,.;$)))))), 𝚤%,.$$)))))), 𝚤%,I1J!"$))))))))), 
and 𝚤%,OPQ$)))))))) represent the noise current from M1, M2, Ibias, and the 
ADC, respectively. According to (4), a simultaneous increase 
in the power consumption from each noise-contributing block 
is necessary to effectively reduce the overall noise. In addition, 
the reduced impedance from the large cell capacitance (CDL) at 
frequencies above 1 kHz causes significant noise peaking and 
dominates the overall noise performance. In other words, there 
exists a noise-power trade-off when interfacing with our 
implantable electrodes. Fig. 7(b) shows an illustration of the 
power spectral density (PSD) where ωpeak is the peaking 
frequency and occurs when  𝚤%,;$)))) = 𝚤%,$$)))). Assuming that the BGR 
noise is effectively filtered, Rs << 1/ωpeakCDL, and each 
component contributes equally, (4) and (5) are lumped to: 
 
 
!',)*"""""∆$  = 𝑁;,𝜔V'!2𝐶PW/$ 	,-./01D ,                      (6) 
 !',)*"""""∆$  = 𝑁$(4𝑘𝑇𝛾𝑔𝑚$).                            (7) 
 
In (6) and (7), gm1 is the transconductance of the input 
transistors in the amplifiers A1-3, gm2 is the transconductance of 
the transistors M1, M2, and Ibias in the current conveyor, k is the 
Boltzmann constant, T is the absolute temperature, γ is the 
technology-dependent noise factor, and N1 and N2 are the 
numbers of noise components. In (6), the output noise voltage 
of the R-2R DAC (with a unit resistor of R0) is converted to the 
input-referred noise of a transistor having an equivalent gm of 
γ/R0. Assuming N1 = N2, we have: 
 𝑔𝑚; ≈ 201@ ,𝜔V'!2𝐶PW/$.                      (8) 
 
With a CDL and gm2 of 100 nF and 30 µS (at Ibias = 2µA), a gm1 
of 26.4 mS is needed for ωpeak at 1 kHz. Such a gm requirement 
leads to excessive-high current (~2 mA per input transistor) for 
an optimistic 150 pArms when integrated over 2.5 kHz of 
bandwidth (not considering the flicker noise and assume brick-
wall filtering). Note that the need for high bandwidth is the main 
difference in power consumption requirement when compared 
to glucose sensors employing fixed-potential amperometry with 
excessive filtering (below few Hz) [32–33].  
 
Fig. 7. (a) The system block diagram of a conventional electrochemical-sensing 
circuit. (b) PSD illustration of noise peaking. 
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C. Sample-and-Hold Sensor Architecture 
Fig. 8 demonstrates the conceptual operation of the proposed 
sample-and-hold (S/H) electrochemical interfacing circuit. The 
central idea is to sample and hold the settled potentials onto 
capacitors C1 and C2 presented at both the reference (RE) and 
working electrodes (WE) using two switches (S1 and S2) such 
that the noise-contributing amplifiers can be disconnected and 
powered down during redox-current recording. Fig. 8(b) and 
8(c) show the two modes of the operation. During the recording 
phase, the input-referred noise (IRN) current is only dominated 
by the common-gate device (M1) and its mirroring load (M2) 
and is insensitive to CDL, leading to superior low noise at low-
power operation. In this way, we have essentially eliminated the 
noise from Eq. (4). The degree of power reduction from this 
duty-cycling method is determined by the duration ratio 
between the tracking and the holding phases. Inevitably, there 
will be sampling noise including those from the amplifiers, 
charge injection, clock feedthrough, and environmental 
electromagnetic interference (EMI). This will cause undesirable 
modulation of the electrode potentials which affect the kinetics 
of the electron transfer, and thus the measurement uncertainty. 
As will be demonstrated later in Section IV-B, this can be 
compensated using principal component analysis (PCA) based 
on the multiple parameters extracted from the measurements.  
In the design, C1 (1 µF, an off-chip ceramic capacitor) is 
chosen to supply a sufficient amount of charge for the redox 
reaction without much perturbation to the electrode potential 
(~1mV under complete redox reaction) while C2 (40 pF, on-
chip MOSCap) is selected to minimize the sampling noise, 
charge injection, and clock feedthrough. As the detection is 
based upon the extraction of the time constant, the impact from 
both the offsets and the flicker noise is minimal. Therefore, 
mitigation techniques such as chopper stabilization and 
correlated double sampling are not incorporated. Due to its 
open-loop nature, the input impedance of the current buffer M1 
is elevated during the recording phase. In turn, this will cause 
drifts in the WE potential by the modulation from the time-
varying redox currents. Therefore, it is critical to supply a 
decent amount of bias current (2 µA) to keep such a modulation 
within an acceptable margin. The simulated input impedance is 
~16 kΩ at the typical corner, and the WE potential deviates no 
more than ~3.3-mV with ±200nA of current change.  
D. Circuits Implementation 
Fig. 9 shows the block diagram, the timing diagram, and the 
schematics of the proposed S/H electrochemical interfacing IC. 
The operation can be separated into four phases. Prior to each 
potential stepping, all the amplifiers are enabled and S1 and S2 
are closed for 1 msec to re-establish the potentials. Upon ±0.2-
V potential stepping, two charge pump switches (S3 and S4) 
embedded inside the WE current conveyor are closed for 400 
µsec for fast charging and discharging. Afterward, a 100-µsec 
linear settling period is allocated, followed by the opening of S1 
and S2 to hold the potentials and to disable the amplifiers. When 
operated continuously, the amplifiers are duty-cycled at 1.5% 
(=1.5msec/100msec). We extract the kinetics of the electron 
transfer rate from the recorded current transients. Most of the 
signal-of-interest lies within the first 10 msec after the potential 
stepping, indicating that the ADC can be further powered off 
during the other 90 msec. Identical Miller-compensated two-
stage amplifiers (Fig. 10(a)) with a tail bias of 320 µA are used 
in the implementation of A1-3 except that the compensation RC 
network is removed for the RE driver (A2). This guarantees the 
settling speed of the amplifiers under a 1-µF load, and also 
serves as benchmarking comparison when configured into a 
conventional electrochemical sensor with feedback enabled. 
Note that the power consumption of A1 and A3 can be further 
 
Fig. 8. (a) Proposed CA with sample-and-hold operation. (b) Simplified circuit 
schematics in the potential-tracking phase. (c) Simplified circuit schematics 
during the hold phase.  
 
Fig. 9. (a) Complete circuit schematics. (b) Operational timing diagram. 
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reduced in the proposed S/H scheme for further power saving. 
The redox current is amplified by the regulated cascode (RGC) 
current mirror with programmable mirror ratio (Fig. 10(b)) and 
is digitized by a dual-slope ADC (Fig. 10(c)). The full scale (0.5 
~ 2 µA) and the integrating capacitance (1b control) in the 
ADC, as well as the RGC mirror ratio (1:8) are made adjustable 
to expand the total dynamic range by nearly 40 dB. No explicit 
filtering stage is incorporated; instead, we rely on the 
integration from the ADC with a window size of 50 µsec and is 
thus sub-optimal. To minimize leakage current during the hold 
phase, S1 and S2 are implemented with tri-switches and an 
analog keeper using a feedback unity-gain buffer (rail-to-rail 
input folded cascode amplifier, Fig. 10(d)). In this prototype 
study, the sensing IC is clocked at 30 MHz with a signal 
generator for testing flexibility. The programmability is offered 
by on-chip scanning registers and finite-state machine (FSM), 
and is controlled with an off-chip FPGA. 
IV. EXPERIMENTAL RESULTS 
A. Electrical Characterization 
The prototype circuit is implemented in TSMC 65-nm 
CMOS technology. Fig. 11 shows the circuit micrograph with 
the core occupying an area of 0.385 mm2, mainly dominating 
by the area of the three OTAs (A1-3). All analog blocks are 
implemented with thick-oxide transistors and is powered from 
a 2.5-V supply through on-chip LDO. The digital circuits are 
operated at 0.9 V. To mitigate EMI, the circuit is powered using 
battery at 3 V, and the whole system is shielded with a Faraday 
cage except the FPGA and the clock source.  
We first perform electrical characterization of the interface 
circuits. Specifically, we evaluate the settling behavior of the 
WE and RE potentials under abrupt changes. With the electrode 
impedance model (at a CDL of 100 nF) shown in Fig. 12(a), VWE 
– VRE achieves complete settling at a maximum stepping 
amplitude of 425mV. This is 2´ the desired amplitude (200 mV) 
given an overestimated CDL, and thus it is sufficient to cover the 
variation in the sensor surface area. Fig. 12(b) also exhibits an 
example case when incomplete settling is also observed.  
Next, we compare the sensor noise performance with and 
without the S/H technique. To do so, a sinusoidal voltage is 
injected through a 1-MΩ off-chip resistor and the samples are 
acquired during the hold phases at an extended time (0.5 sec). 
Fig. 13 compares the measurement results. Without the S/H, 
high-frequency noise-peaking from the 100-nF CDL is 
observable and the integrated noise over 2.5 kHz is 4.36 nArms. 
 
Fig. 10. Circuit schematics: (a) OTAs. (b) RGC. (c) Dual-slope ADC. (d) Tri-
switch. (e) R-2R DAC. 
 
 
Fig. 11. Circuit micrograph. 
 
 
Fig. 12. (a) Measured potentials 
 
 
Fig. 13. Measured time-domain waveforms and PSDs with S/H: (a) disabled 
and (b) enabled. 
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On the other hand, a minimum IRN of 15.2 pArms is measured 
with S/H enabled and stays insensitive to different CDL loading. 
The measured 1/f corner-frequency is ~300Hz. In these 
electrical testing, the mirror gain and the ADC parameters are 
adjusted accordingly to ensure low quantization noise. When 
interfacing with the aptamer sensors, these parameters are re-
adjusted according to the measured current level. The 
maximum current that the current conveyor can measure is 1.6 
µApp with HD2 of 45 dB. The instantaneous dynamic range (DR) 
is about 60dB, which is sufficient in our application. The cross-
range DR is ~100 dB (= 1.6 µApp  / 15.2 pArms).  
The 10-bit R-2R DAC has a DNL and INL of +0.9/-0.58 and 
+1.2/-0.65 LSB, respectively. Based on our assay experiments, 
the requirement in the absolute accuracy is not as stringent so 
long as it is consistent across measurements. The circuit 
consumes 5.25 mW at 2.5 V without the S/H technique. Once 
S/H is enabled, all the power-hungry OTAs (but not ADC) are 
duty-cycled, reducing the total power to 0.22 mW.  
B. Assay Experiments 
We prepare a two-electrode sensing probe functionalized 
with aminoglycoside aptamers and carry out the assay in target-
spiked human whole-blood samples in vitro. The 
immobilization steps are similar to those in [15] and are 
summarized as follows: (1) define the sensor surface area on the 
gold electrode using heat-shrink tubing; (2) perform 
electrochemical cleaning in 0.5- and 0.05-M H2SO4 solution 
using three CV scans at 100 mV/sec from -0.4 to 1.5 V; (3) 
incubate the sensor surface with 1-µM aptamer solution in 
saline sodium citrate (1´ SSC) buffer for an hour at room 
temperature; (4) passivate the sensor surface with 6-mercapto-
1-hexanol (MCH) at 6 mM in DI-water for two hours at room 
temperature; (5) store the device in 1´ SSC at 4°C overnight to 
stabilize the SAM layer. Afterward, the device is ready to use 
and has a shelf life of one week. The human whole blood 
samples are purchased from BioIVT Inc. and are spiked with 
200-mM kanamycin monosulfate (prepared in 1´ SSC buffer) 
followed by serial dilution to the desired concentrations. To 
avoid sample contamination, we manually swap sample tubes 
 
Fig. 14. (a) Measured electrode waveforms when interfacing with an aptamer 
device. (b) A zoom-in of the first pulse. (c) Waveforms during the hold phases.  
 
 
Fig. 15. Measured normalized current responses. 
 
Fig. 16. Extracted τ1 and I1. 
 
 
Fig. 17. Extracted principal component (a) vs. time and (b) vs. concentration. 
Error bar stands for one standard deviation. 
 
Table III. Performance Comparison 
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and perform chronoamperometry testing. We record VWE and 
VRE as well as the current transients for analysis. 
Fig. 14 presents the measured VWE – VRE waveforms with the 
actual aptamer-immobilized sensing device to study its settling 
and drooping. This is particularly important as the cell 
impedance critically depends on the integrity and the quality of 
the self-assembly monolayer (SAM). From Fig. 14(c), voltage 
changes in the region-of-interest (ROI, the first 10 msec after 
potential stepping) is ~ 4.5 mV, and its shape is correlated to 
the exponentially changing current transients.  The drooping 
over a half-cycle duration (50 msec) is ~0.2 V/sec, indicating 
there exists a constant background leakage current of ~2 nA 
(assuming CDL of 10 nF) and can be viewed as the “offset” 
current caused by the pinholes in the SAM. A 3-mVpp sampling 
error in VWE – VRE is observed from 20 consecutive recorded 
pulses, as shown in Fig. 14(a). This is much higher than the 
simulated sampling noise from the circuits alone and is 
therefore attributed to the finite pick-up from EMI effects. Such 
a sampling noise indeed affects the extracted kinetics and we 
will present a compensation technique in the next paragraph.  
Fig. 15 shows the measured kinetics from normalized current 
transients at 0, 0.5, and 2 mM kanamycin concentration. 
Difference in the electron transfer kinetics at different target 
concentrations is observed. Next, we fit the un-normalized 
current transients using a two-term exponential function shown 
below to extract both the kinetics (τ1 and τ2) and the absolute 
current level (I1 and I2): 𝑖(𝑡) = 𝐼+𝑒& !"$ + 𝐼$𝑒& !"% .	                         (9) 
Fig. 16 plots the extracted τ1 and I1 at different concentration 
levels. Two observations are made from this figure. First, at 
each concentration, there exists high uncertainty in τ1. The 
extracted limit-of-detection (LoD, defined as SNR = 1) is 57 
µM (11% of KD). We attribute this to the random modulation in 
the electrode potentials during the S/H operation. In other 
words, in each chronoamperometric cycle, the perturbation on 
the held potentials causes slight modulation in the electron 
transfer kinetics, as described by the Butler-Volmer model [41]. 
Second, there exists a strong correlation between τ1 and I1, and 
we believe I1 serves as an indirect indicator for the sampled 
electrode potential. By taking advantage of this, we perform 
principal component analysis (PCA) to effectively compensate 
for the measured uncertainty. Fig. 17(a) plots the time series of 
the principal components after rotating the data. A significant 
reduction in the noise variance is demonstrated. Fig. 17(b) plots 
the principal components (mean and standard deviation) at 
different concentrations. An improvement in limit-of-detection 
from 57 to 12.3 µM is achieved. As chronoamperometry offers 
high temporal resolution (5 ~ 10 Hz), we further perform 10-
point boxcar averaging to understand its detection limit and to 
compare with those measured using SWV. An LoD of 3.1 µM 
is measured at an acquisition rate of 1 Hz with drifts removed. 
Table III compares the molecular resolution acquired from 
different electronics and voltammetry techniques and Table IV 
provides a comparison with the state-of-the-art electrochemical 
sensing circuits. The use of S/H technique reduces both the 
circuit noise and the power consumption by a factor of 286´ 
and 23´, respectively, increases the temporal resolution by 80´ 
(or 8´ with averaging), and improves LoD by 1.45´ (or 5.8´).   
V.  CONCLUSION 
In this work, we present the design and the analysis of an 
electrochemical circuit whose input-referred current noise is 
insensitive to the electrode capacitive loading to enable low-
power monitoring of therapeutic drugs using redox-labeled 
structure-switching aptamers. We take advantage of the 
waveform simplicity in chronoamperometry and incorporate 
sample-and-hold operation around the electrochemical cell to 
store the desired electrode potentials using noiseless capacitors 
during the current-recording phase. In the proposed solution, 
the noise dominating OTAs are disconnected from the sensor 
and can be disabled, and simultaneous low-power and low-
noise recording is achieved. We recorded an IRN of 15.2 pArms, 
and the performance is insensitive to the size of the cell-
capacitance. We also addressed the issue of sampling error on 
the held potential using PCA-based signal processing. Using 
these strategies, we achieved an LoD of 3.1 µM in kanamycin 
concentration using an aminoglycoside aptamer with a KD of 
Table IV. Comparison Table 
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0.5 mM. This LoD is > 5´ better than those measured using 
standard SWV (without S/H) yet showing ~23´ lower power 
consumption. Given that aptamer switches can be synthesized 
for a wide range of molecules, we believe our aptamer/CMOS 
platform could be used for many applications in healthcare. One 
exciting direction is the use of our S/H CA sensor for wearable 
or implantable systems.  This will require strategies for 
mitigating the effect of EMI including shielding of the sensing 
probe or differential measurements using multiple channels. 
These topics are potential avenues for future research. 
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